A problem facing companies in the proteomics space is the gap between the data proteomics companies generate and the therapeutic relevance of those data. Many technologies do not provide information on whether a given protein is active or inactive in a disease state. In addition, low abundance proteins may go undetected, and thus potential therapeutics remain undiscovered.

ActivX Biosciences Inc. is working to address both issues with its high throughput chemistry-based proteomics platform, which allows for the identification and analysis of active proteins in all ranges of abundance.